Heparin to be less potent, FDA says

Share this article:
Manufacturers are expected to begin shipping a new kind of heparin product on Thursday.

Pharmacopeia has adopted new manufacturing controls for the anti-clotting drug. These include a revised reference standard for the drug's dose unit to guard against potential contamination. The revised standard is about 10% less potent than the former USP unit. The Food and Drug Administration last week notified healthcare providers of the change.

“Although the FDA-approved labeling for heparin has not changed, including the recommended doses, it is essential that health care professionals be aware of the potential difference in potency between the old and new vials of heparin when administering the drug,” said John Jenkins, director of the FDA's Office of New Drugs.

Share this article:

More in News

NY nursing home agrees to $2.2 million settlement in case of false documentation

NY nursing home agrees to $2.2 million settlement ...

Nursing home operator Ralex Services Inc. has agreed to a $2.2 million settlement in a whistleblower case involving forged documents at a facility in New Rochelle, New York.

Common soaps could endanger healthcare workers, study finds

Healthcare facilities should consider replacing antibacterial soaps containing the chemical triclosan, University of California-San Francisco researchers assert in a recent Journal of Occupational and Environmental Medicine article. The conclusion echoes recently updated hand hygiene guidelines.

Mandatory staff hours, better high-acuity care could improve quality of life in ...

A nursing home's staffing patterns and admissions trends are among the most important factors driving residents' quality of life over time, according to recently published research findings.